样式: 排序: IF: - GO 导出 标记为已读
-
Leveraging Generational Differences in the Gastroenterology Workforce to Promote Satisfaction and a Harmonious Work Environment Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-27 Jennifer M. Kolb, Elizabeth Magnan, John M. Carethers, Swati G. Patel
-
The Cost of Inflammatory Bowel Disease Care – How to Make it Sustainable Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-14 Johan Burisch, Jennifer Claytor, Inmaculada Hernandez, Jason Ken Hou, Gilaad G. Kaplan
The rising global prevalence of inflammatory bowel diseases (IBDs), such as Crohn’s disease and ulcerative colitis, underscores the need to examine current and future IBD care costs. Direct health care expenses, including ambulatory visits, hospitalizations, and medications, are substantial, averaging $9,000 to $12,000 per person annually in high-income regions. However, these estimates do not fully
-
Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-13 David Fudman, Ryan A. McConnell, Christina Ha, Siddharth Singh
The therapeutic armamentarium for management of inflammatory bowel diseases has expanded dramatically in the last 5 years, with the introduction of several medications with different mechanisms of action. These include the oral small molecule drugs Janus kinase inhibitors (including upadacitinib approved for Crohn’s disease and ulcerative colitis [UC], and tofacitinib, approved for UC) and sphingosphine
-
Symptom Profile of Patients With Intestinal Methanogen Overgrowth: A Systematic Review and Meta-analysis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-13 Sepideh Mehravar, Will Takakura, Jiajing Wang, Mark Pimentel, Jason Nasser, Ali Rezaie
Archaea constitute one of the main 3 domains of the tree of life, distinct from eukaryotes and bacteria. Excessive luminal loads of methanogenic archaea (intestinal methanogen overgrowth [IMO]) have been implicated in the pathophysiology of various diseases, including constipation. To elucidate the phenotypical presentation of IMO, we performed a systematic review and meta-analysis of the prevalence
-
Effects of Glucagon-Like Peptide-1 Receptor Agonists on Upper Gastrointestinal Endoscopy: A Meta-Analysis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-12 Antonio Facciorusso, Daryl Ramai, Jahnvi Dhar, Jayanta Samanta, Saurabh Chandan, Paraskevas Gkolfakis, Stefano Francesco Crinò, Marcello Maida, Andrea Anderloni, Ivo Boskoski, Konstantinos Triantafyllou, Mario Dinis-Ribeiro, Cesare Hassan, Lorenzo Fuccio, Marianna Arvanitakis
Limited evidence exists regarding the impact of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on upper endoscopy. Therefore, a meta-analysis was conducted to comprehensively review the available evidence on this subject. A systematic bibliographic search was carried out until May 2024. Pooled estimates were analyzed using a random-effects model, with results presented as odds ratio (OR) and
-
Perianal Fistulizing Crohn’s Disease: Utilizing the TOpClass Classification in Clinical Practice to Provide Targeted Individualized Care Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-10 Luke N. Hanna, Sulak Anandabaskaran, Nusrat Iqbal, Jeroen Geldof, Jean-Frédéric LeBlanc, Anders Dige, Lilli Lundby, Séverine Vermeire, André D’Hoore, Bram Verstockt, Gabriele Bislenghi, Danny De Looze, Triana Lobaton, Dirk Van de Putte, Antonino Spinelli, Michele Carvello, Silvio Danese, Christianne J. Buskens, Krisztina Gecse, Roel Hompes, Marte Becker, Jarmila van der Bilt, Wilhelmus Bemelman, Shaji
Perianal fistulation is a challenging phenotype of Crohn’s disease, with significant impact on quality of life. Historically, fistulae have been classified anatomically in relation to the sphincter complex, and management guidelines have been generalized, with lack of attention to the clinical heterogenicity seen. The recent ‘TOpClass classification system’ for perianal fistulizing Crohn’s disease
-
Generative Artificial Intelligence Tools in Gastroenterology Training Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-06 Tasnim Ahmed, Loren G. Rabinowitz, Adam Rodman, Tyler M. Berzin
-
Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of Art Update Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-31 Silvia Sookoian, Yaron Rotman, Luca Valenti
Recent advances in the genetics of metabolic dysfunction-associated steatotic liver disease (MASLD) are gradually revealing the mechanisms underlying the heterogeneity of the disease and have shown promising results in patient stratification. Genetic characterization of the disease has been rapidly developed using genome-wide association studies, exome-wide association studies, phenome-wide association
-
Prevalence of Endoscopically Curable Low-Risk Cancer Among Large (≥20 mm) Nonpedunculated Polyps in the Right Colon Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-31 Julia L. Gauci, Anthony Whitfield, Renato Medas, Clarence Kerrison, Francesco Vito Mandarino, David Gibson, Timothy O’Sullivan, Oliver Cronin, Sunil Gupta, Brian Lam, Varan Perananthan, Luke Hourigan, Simon Zanati, Rajvinder Singh, Spiro Raftopoulos, Alan Moss, Gregor Brown, Amir Klein, Lobke Desomer, David J. Tate, Steven J. Williams, Eric Y. Lee, Nicholas Burgess, Michael J. Bourke
Endoscopic submucosal dissection is increasingly promoted for the treatment of all large nonpedunculated colorectal polyps (LNPCPs) to cure potential low-risk cancers (superficial submucosal invasion without additional high-risk histopathologic features). The effect of a universal en bloc strategy on oncologic outcomes for the treatment of LNPCPs in the right colon is unknown. We evaluated this in
-
Double Wire Cannulation and Mechanical Lithotripsy in Billroth II With Therapeutic Gastroscope Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-31 Grace E. Kim, Uzma D. Siddiqui
-
Tenofovir Is Associated With a Better Prognosis Than Entecavir for Hepatitis B Virus–Related Hepatocellular Carcinoma Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-31 Sung Won Chung, Hyun Jun Um, Won-Mook Choi, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee
Whether tenofovir or entecavir has different effects on the prevention of hepatitis B virus (HBV)–related hepatocellular carcinoma (HCC) in secondary and tertiary preventive settings is still a matter of debate. This study aimed to compare the long-term prognosis of HCC between tenofovir and entecavir in patients with chronic hepatitis B. Chronic hepatitis B patients diagnosed with HCC between November
-
Proton Pump Inhibitors Are Recommended for Patients on Dual Antiplatelet Agents and Also for Patients on Anticoagulant Plus Aspirin Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-31 Marvin Chinitz
-
Trainee Participation and Outcomes in High-risk Endoscopic Retrograde Cholangiopancreatography: A Secondary Analysis of the Stent Versus Indomethacin Trial Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-31 Sachin Wani, Jingwen Zhang, Lydia D. Foster, Valerie Durkalski-Mauldin, B. Joseph Elmunzer, Stent Versus Indomethacin (SVI) Study Group, Jose Serrano, Gregory A. Coté, Steven A. Edmundowicz, Raj Shah, Ji Young Bang, Shyam Varadarajulu, Vikesh K. Singh, Mouen Khashab, Richard S. Kwon, James M. Scheiman, Field F. Willingham, Steven A. Keilin, Georgios I. Papachristou, Amitabh Chak, Adam Slivka, Daniel
-
Biomarkers for Prediction of Alcohol-Related Liver Cirrhosis: A General Population–Based Swedish Study of 537,250 Individuals Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-31 Gustav Jakobsson, Mats Talbäck, Niklas Hammar, Ying Shang, Hannes Hagström
The study sought to examine which biomarkers have the best predictive capabilities for future alcohol-related liver cirrhosis (ARLC) in a general population setting. This population-based cohort study includes approximately 35% of the inhabitants of Stockholm County who had left a blood sample at an outpatient visit in primary care or occupational health screening from 1985 to 1996. All subjects with
-
Live Rotavirus Vaccination Appears Low-risk in Infants Born to Mothers With Inflammatory Bowel Disease on Biologics Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-31 Kenneth Ernest-Suarez, Luis E. Murguía-Favela, Cora Constantinescu, Tiffany Fitzpatrick, Karina A. Top, Jia Hu, Taj Jadavji, Yvette Leung, Melissa Chan, Remo Panaccione, Cynthia H. Seow
Biologic therapies in the context of inflammatory bowel disease and pregnancy lead to improved maternal and fetal outcomes. Placental transfer results in detectable drug concentrations in infants. Rotavirus infection results in diarrheal related hospitalizations; however, the live oral vaccine is not currently recommended in biologic exposed infants. The aim of this study was to assess the effect of
-
Endoscopic, Histologic, and Composite Endpoints in Patients With Ulcerative Colitis Treated With Etrasimod Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-31 Fernando Magro, Laurent Peyrin-Biroulet, Bruce E. Sands, Silvio Danese, Vipul Jairath, Martina Goetsch, Abhishek Bhattacharjee, Joseph Wu, Diogo Branquinho, Irene Modesto, Brian G. Feagan
Histologic remission, a potentially important treatment target in ulcerative colitis (UC), is associated with favorable long-term outcomes. Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate (S1P) receptor modulator for the treatment of moderately to severely active UC. This post-hoc analysis of the ELEVATE UC program evaluated the efficacy of etrasimod according to histologic and
-
Development and Validation of a Noninvasive Model for the Detection of High-Risk Varices in Patients with Unresectable HCC Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-30 Neehar D. Parikh, Patricia Jones, Reena Salgia, Irun Bhan, Lauren T. Grinspan, Janice H. Jou, Kali Zhou, Prasun Jalal, Giorgio Roccaro, Amol S. Rangnekar, Jihane N. Benhammou, Anjana Pillai, Neil Mehta, Joel Wedd, Ju Dong Yang, Amy K. Kim, Andres Duarte-Rojo, Omobonike O. Oloruntoba, Amit Tevar, Jennifer S. Au, Yamile Blain, Sanjana Rao, Onofrio A. Catalano, Sara Lewis, Mishal Mendiratta-Lala, Kevin
Noninvasive variceal risk stratification systems have not been validated in patients with hepatocellular carcinoma (HCC), which presents logistical barriers for patients in the setting of systemic HCC therapy. We aimed to develop and validate a noninvasive algorithm for the prediction of varices in patients with unresectable HCC. We performed a retrospective cohort study in 21 centers in the United
-
Baseline and Dynamic MAF-5 Score to Predict Liver Fibrosis and Liver-Related Events in General Population With MASLD Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-30 Shanghao Liu, Xuanwei Jiang, Junliang Fu, Vincent Wai-Sun Wong, Victor W. Zhong, Xiaolong Qi
-
-
Performance of a Multi-cancer Early Detection Test for Detection of Hepatocellular Carcinoma in Patients With Cirrhosis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-27 Darine Daher, Purva Gopal, Marie V. Coignet, Vivian Xiao, Kathryn N. Kurtzman, Amit G. Singal
-
Noninvasive Fibrosis Tests Require Further Evaluation in At-risk Populations Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-27 Janakan Selvarajah, Spiros Fourlanos, Ashok Raj
-
Defining and Understanding Diagnostic Delays Among Pancreatic Cancer Patients: A Retrospective Cohort Study Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-27 Natalia Khalaf, Yan Liu, Jennifer R. Kramer, Hashem B. El-Serag, Fasiha Kanwal, Hardeep Singh
Pancreatic cancer is a lethal cancer of increasing incidence, presenting with several clinically detectable signals allowing for earlier diagnosis. However, there are limited data related to diagnostic process, including prevalence of diagnostic delays and their contributing factors. We aimed to develop a standardized definition of diagnostic delay, evaluate its prevalence, and identify its contributing
-
Clinical Presentation and Outcomes of Alpha-Gal Syndrome Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-26 Elvira Lesmana, Sameer Rao, Ashley Keehn, Adam L. Edwinson, Ashima Makol, Madhusudan Grover
Alpha-gal syndrome (AGS) is an IgE-mediated allergic reaction to galactose-α-1,3-galactose, primarily linked with Lone Star tick bites in the United States. It presents with symptoms ranging from urticaria and gastrointestinal (GI) manifestations to delayed anaphylaxis following red meat consumption. We aimed to study AGS patients' clinical manifestations, diagnosis, and outcomes. A retrospective chart
-
Risk of De Novo Barrett’s Esophagus Post Sleeve Gastrectomy: A Systematic Review and Meta-Analysis of Studies with Long-Term Follow-Up Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-25 Saurabh Chandan, Shahab R. Khan, Smit S. Deliwala, Dushyant S. Dahiya, Babu P. Mohan, Daryl Ramai, Syed M. Saghir, Banreet S. Dhindsa, Lena L. Kassab, Antonio Facciorusso, Kalyana Nandipati, Dennis Yang, Douglas G. Adler
Sleeve gastrectomy (SG) is one of the most commonly performed bariatric procedures worldwide. Gastroesophageal reflux disease (GERD) is a major concern in patients undergoing SG and is a risk factor for Barrett’s esophagus (BE). We conducted a systematic review and meta-analysis to assess the incidence of and analyze predictive factors for post-SG BE. A comprehensive literature search was conducted
-
Automated Neutrophil Quantification and Histological Score Estimation in Ulcerative Colitis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-25 Jun Ohara, Yasuharu Maeda, Noriyuki Ogata, Takanori Kuroki, Masashi Misawa, Shin-ei Kudo, Tetsuo Nemoto, Toshiko Yamochi, Marietta Iacucci
In the management of ulcerative colitis (UC), histological remission is increasingly recognized as the ultimate goal. The absence of neutrophil infiltration is crucial for assessing remission. This study aimed to develop an artificial intelligence (AI) system capable of accurately quantifying and localizing neutrophils in UC biopsy specimens to facilitate histological assessment. Our AI system, which
-
Diffuse Large B-Cell Duodenal Lymphoma Presenting with Obstruction and Pneumatosis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-25 Ramzi Hassouneh, Michael Morton, Christen K. Dilly
-
Comments on "Enduring Clinical Remission in Refractory Celiac Disease Type II with Tofacitinib: An Open-Label Clinical Study" Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-25 Manjeet Kumar Goyal
-
The IBD Clinic of Tomorrow: Holistic, Patient-Centric, and Value-based Care Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-25 Benjamin Click, Raymond K. Cross, Miguel Regueiro, Laurie Keefer
There is increasing recognition of the associated bi-directional impact of inflammatory bowel disease (IBD) on patient well-being and the potential benefit of multidisciplinary teams to address these unique needs. At certain IBD centers, there has been an evolution towards patient-centric, holistic care to enhance well-being and improve health-related outcomes. Multiple models, incorporating various
-
IBD Matchmaking - Rational Combination Therapy Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-25 Robert Battat, John T. Chang, Edward V. Loftus Jr, Bruce E. Sands
A growing number of patients with Crohn’s disease and ulcerative colitis have disease that is refractory to multiple advanced therapies, have undergone multiple surgeries, and require further treatment options. For this reason, there has been increasing use of multiple simultaneous advanced targeted therapies. Although the knowledge on combined advanced targeted therapy (CATT) in inflammatory bowel
-
Esophageal Large-Cell Neuroendocrine Carcinoma Mimicking Benign Submucosal Tumor Treated with Endoscopic Submucosal Dissection Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-23 Jiao Li, Zhengkui Zhou, Xiaobin Sun
-
Association Between Deep Sedation and Risk of Post-colonoscopy Colorectal Cancer: Swedish Register Data 2007-2016 Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-23 Anna Forsberg, Linnea Widman, Anna Andreasson
-
Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients with MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-20 Mazen Noureddin, Michael R. Charlton, Stephen A. Harrison, Meena B. Bansal, Naim Alkhouri, Rohit Loomba, Arun J. Sanyal, Mary E. Rinella
-
Disparities for Hispanic Adults With Metabolic Dysfunction-associated Steatotic Liver Disease in the United States: A Systematic Review and Meta-analysis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-16 Kaleb Tesfai, Jordan Pace, Nora El-Newihi, Maria Elena Martinez, Monica Tincopa, Rohit Loomba
Prevalence and severity of metabolic dysfunction-associated steatotic liver disease (MASLD) is reported to be higher in Hispanic adults in the United States (U.S.), although rates vary substantially across studies and have increased given the evolving obesity epidemic. This systematic review and meta-analysis quantifies MASLD disease burden and severity in contemporary cohorts to characterize health
-
Mucosal Healing with Vedolizumab in Patients with Chronic Pouchitis: EARNEST, a Randomized, Double-Blind, Placebo-Controlled Trial Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-16 Vipul Jairath, Brian G. Feagan, Mark S. Silverberg, Silvio Danese, Paolo Gionchetti, Mark Löwenberg, Brian Bressler, Marc Ferrante, Ailsa Hart, Dirk Lindner, Armella Escher, Stephen Jones, Bo Shen, Simon Travis
Vedolizumab is indicated for the treatment of chronic pouchitis in the European Union. We assessed whether vedolizumab induced mucosal healing (MH) and if MH was associated with clinical improvements. EARNEST, a randomized, double-blind, placebo-controlled study, evaluated vedolizumab efficacy and safety in adults with chronic pouchitis. Centrally read endoscopic and histologic evaluation was performed
-
The Future of Clinical Trials in Inflammatory Bowel Disease Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-16 Christopher Ma, Virginia Solitano, Silvio Danese, Vipul Jairath
The medical management of inflammatory bowel disease (IBD) has been transformed over the past few decades by the approval of multiple classes of advanced therapies and the integration of more targeted treatment strategies for Crohn’s disease and ulcerative colitis. These changes have been driven by an increasing number of pivotal randomized controlled trials, which have grown in size and complexity
-
Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-15 Laurent Lam, Pierre-Antoine Soret, Sara Lemoinne, Bettina Hansen, Gideon Hirschfield, Aliya Gulamhusein, Aldo J. Montano-Loza, Ellina Lytvyak, Albert Parés, Ignasi Olivas, Maria-Carlota Londono, Sergio Rodríguez-Tajes, John E. Eaton, Karim T. Osman, Christoph Schramm, Marcial Sebode, Ansgar W. Lohse, George Dalekos, Nikolaos Gatselis, Frederik Nevens, Nora Cazzagon, Alessandra Zago, Francesco Paolo
In primary biliary cholangitis (PBC), static liver stiffness measurement (LSM) has proven prognostic value. However, the added prognostic value of LSM time course in this disease remains uncertain. We conducted an international retrospective cohort study among patients with PBC treated with ursodeoxycholic acid and followed by vibration-controlled transient elastography between 2003 and 2022. Using
-
Practice Innovations to Optimize GI Access by Enhancing Existing Supply and Right-Sizing Demand Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-15 Shirley Cohen-Mekelburg, Sameer D. Saini, Megan A. Adams
-
Setting a Value for Novel GERD treatments Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-14 Fouad Otaki, John O. Clarke
-
A Practical Approach to Navigating Relevance, Regulatory, and Reimbursement in Gastroenterology Innovation for Gastroenterology Trainees Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-14 Mythili P. Pathipati, Eric D. Shah
-
Evaluating Real-world Consistency and Accuracy by ChatGPT4 for Post-colonoscopy Follow-up Recommendations Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-10 Patrick W. Chang, James L. Buxbaum, Ara B. Sahakian
-
Prediction and Prevention of Inflammatory Bowel Disease Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-10 Emily W. Lopes, Williams Turpin, Kenneth Croitoru, Jean-Frederic Colombel, Joana Torres
-
AGA Clinical Practice Update on the Role of Intestinal Ultrasound in Inflammatory Bowel Disease: Commentary Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-10 Mallory Chavannes, Michael Todd Dolinger, Shirley Cohen-Mekelburg, Bincy Abraham
In the past 3 years, the use of intestinal ultrasound (IUS) for monitoring inflammatory bowel disease in clinical practice has grown substantially in the United States. This American Gastroenterological Association (AGA) Institute Clinical Practice Update (CPU) aims to review the available evidence and guidance regarding the role of intestinal ultrasound in inflammatory bowel disease care. This CPU
-
Drug-induced Liver Injury in Latin America: 10-year Experience of the Latin American DILI (LATINDILI) Network Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-09 Fernando Bessone, Nelia Hernandez, Inmaculada Medina-Caliz, Miren García-Cortés, María I. Schinoni, Manuel Mendizabal, Daniela Chiodi, Vinicius Nunes, Ezequiel Ridruejo, Ximena Pazos, Genario Santos, Eduardo Fassio, Raymundo Parana, Virginia Reggiardo, Hugo Tanno, Adriana Sanchez, Federico Tanno, Pedro Montes, Martin Tagle, Marco Arrese, Javier Brahm, Marcos Girala, M. Isabel Lizarzabal, Enrique Carrera
Latin America is a region of great interest for studying the clinical presentation of idiosyncratic drug-induced liver injury (DILI). A comprehensive analysis of patients enrolled into the LATINDILI Network over a decade is presented. Demographics, clinical presentation, histological findings and outcome of prospectively recruited DILI cases in the LATINDILI Network were analyzed. Suspected culprit
-
Diet and Microbiome-Directed Therapy 2.0 for IBD Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-09 Ashwin N. Ananthakrishnan, Kevin Whelan, Jessica R. Allegretti, Harry Sokol
Inflammatory bowel disease (IBD) comprises chronic and relapsing disorders of the gastrointestinal tract, characterized by dysregulated immune responses to the gut microbiome. The gut microbiome and diet are key environmental factors that influence the onset and progression of IBD and can be leveraged for treatment. In this review, we summarize the current evidence on the role of the gut microbiome
-
How Artificial Intelligence Will Transform Clinical Care, Research, and Trials for Inflammatory Bowel Disease Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-09 Anna L. Silverman, Dennis Shung, Ryan W. Stidham, Gursimran S. Kochhar, Marietta Iacucci
Artificial intelligence (AI) refers to computer-based methodologies that use data to teach a computer to solve pre-defined tasks; these methods can be applied to identify patterns in large multi-modal data sources. AI applications in inflammatory bowel disease (IBD) includes predicting response to therapy, disease activity scoring of endoscopy, drug discovery, and identifying bowel damage in images
-
Global Prevalence, Clinical Characteristics, Surveillance, Treatment Allocation, and Outcomes of Alcohol-Associated Hepatocellular Carcinoma Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-08 Rebecca Wenling Zeng, Christen En Ya Ong, Elden Yen Hng Ong, Charlotte Hui Chung, Wen Hui Lim, Jieling Xiao, Pojsakorn Danpanichkul, Jia Hao Law, Nicholas Syn, Douglas Chee, Alfred Wei Chieh Kow, Sung Won Lee, Hirokazu Takahashi, Takumi Kawaguchi, Nobuharu Tamaki, Yock Young Dan, Atsushi Nakajima, Karn Wijarnpreecha, Mark D. Muthiah, Mazen Noureddin, Rohit Loomba, George N. Ioannou, Darren Jun Hao
Although the burden of alcohol-associated hepatocellular carcinoma (HCC) is increasing with rising alcohol consumption, clinical presentation and outcomes of alcohol-associated HCC have not been systematically assessed. We aimed to determine the prevalence, clinical characteristics, surveillance rates, treatment allocation, and outcomes of alcohol-associated HCC. Medline and Embase were searched from
-
Transcriptomic and Metabolomic Correlates of Increased Colonic Permeability in Postinfection Irritable Bowel Syndrome Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-08 Ana Y. Caceres Lessa, Adam Edwinson, Hiroki Sato, Lu Yang, Antonio Berumen, Margaret Breen-Lyles, Anjali Byale, Michael Ryks, Ashley Keehn, Michael Camilleri, Gianrico Farrugia, Jun Chen, Marijke Decuir, Kirk Smith, Surendra Dasari, Madhusudan Grover
Postinfection irritable bowel syndrome (PI-IBS) is well-known epidemiologically; however, its physiological and molecular characteristics are not well studied. We aimed to determine the physiological phenotypes, colonic transcriptome, fecal microbiome, and metabolome in PI-IBS. Fifty-one Rome III PI-IBS patients and 39 healthy volunteers (HV) were enrolled. Participants completed questionnaires, in vivo
-
The Prevalence and Rate of Undiagnosed Celiac Disease in an Adult General Population, the Trøndelag Health Study, Norway Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-08 Polina Lukina, Ina L. Andersen, Rolf A. Klaasen, David J. Warren, Nils Bolstad, Patricia Mjønes, Elin Rønne, Rasmus Iversen, Ludvig M. Sollid, Knut E.A. Lundin, Eivind Ness-Jensen
This study aimed to determine the total prevalence of celiac disease (CeD), including undiagnosed cases, in a population-based study of adults screened for CeD. The study used the fourth Trøndelag Health Study (HUNT4), conducted in 2017–2019, where 56,042 adult (aged >20 years) residents of Nord-Trøndelag County, Norway, participated. Serum samples from 54,505 participants were analyzed for anti-transglutaminase
-
-
Jejunal Gastric Heterotopia Causing Iron Deficiency Anemia Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-06 Cautar El Maimouni, Alba Vargas García, Begoña González-Suárez
-
Applicability of the International Bowel Ultrasound Segmental Activity Score to Ulcerative Colitis: A Preliminary Study Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-05 Tommaso Innocenti, Carmen Rocco, Erica Nicola Lynch, Monica Milla, Andrea Galli, Gabriele Dragoni
-
Prevalence of Liver Steatosis and Fibrosis in Adults With Primary Hypobetaliproteinemia: Results From the HYPOCHOL Study Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-05 Sarra Smati, Matthieu Wargny, Jerome Boursier, Philippe Moulin, Mathilde Di Filippo, Bertrand Cariou
-
Additional Yield of Random Biopsy in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-05 Li Gao, Ke Fang, Xin Dong, Jiawei Bai, Kai Liu, Yue Wang, Mi Wang, Ying Han, Zhiguo Liu
There are limited clinical data regarding the additional yields of random biopsies (RBs) during colorectal cancer surveillance in patients with inflammatory bowel disease. To assess the additional yield of RB, a systematic review and meta-analysis was conducted. PubMed, Embase, Web of Science, and the Cochrane Library were searched for studies investigating the preferred colonoscopy surveillance approach
-
Endoscopic Glue Injection vs Glue Plus BRTO or TIPSS for Preventing Gastric Variceal Bleeding: A Randomized Controlled Trial Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-04 Sagnik Biswas, Manas Vaishnav, Shivanand Gamanagatti, Shekhar Swaroop, Umang Arora, Arnav Aggarwal, Anshuman Elhence, Deepak Gunjan, Saurabh Kedia, Soumya Jagannath Mahapatra, Ashwani Kumar Mishra, Shalimar
The study sought to compare the efficacy of endoscopic injection sclerotherapy with cyanoacrylate glue (EIS-CYA) vs EIS-CYA plus a radiologic intervention (RI) (either transjugular intrahepatic portosystemic shunt or balloon-occluded retrograde transvenous obliteration) for secondary prophylaxis in patients with liver cirrhosis who presented with acute variceal bleeding from cardiofundal varices. Primary
-
After Surgically Induced Remission, Ileal and Colonic Mucosa-Associated Microbiota Predicts Crohn’s Disease Recurrence Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-04 Cristian Hernández-Rocha, Williams Turpin, Krzysztof Borowski, Joanne M. Stempak, Ksenija Sabic, Kyle Gettler, Christopher Tastad, Colleen Chasteau, Ujunwa Korie, Mary Hanna, Abdul Khan, Emebet Mengesha, Alain Bitton, Marc B. Schwartz, Arthur Barrie, Lisa W. Datta, Mark Lazarev, Steven R. Brant, John D. Rioux, Dermot P.B. McGovern, Richard H. Duerr, L. Phil Schumm, Judy H. Cho, Mark S. Silverberg
Investigating the tissue-associated microbiota after surgically induced remission may help to understand the mechanisms initiating intestinal inflammation in Crohn’s disease. Patients with Crohn’s disease undergoing ileocolic resection were prospectively recruited in 6 academic centers. Biopsy samples from the neoterminal ileum, colon, and rectosigmoid were obtained from colonoscopies performed after
-
Vibration-Controlled Transient Elastography–Based Parameters Predict Clinical Outcomes in Liver Transplant Recipients Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-04 Alok Baral MD, Shreya Garg MD, Madison Nguyen MD, Rehan Razzaq MD, Audrey Ang MD, Hiba Khan MD, Dylan Vainer MD, Vaishali Patel MD, Geneva Roache BS, Mark Muthiah MBBS, Idris Yakubu PharmD, Vinay Kumaran MBBS MS, Anh T. Bui PhD, Mohammad Shadab Siddiqui MD
Vibration-controlled transient elastography (VCTE) is used in clinical practice to risk-stratify liver transplant (LT) recipients; however, there are currently little data demonstrating the relationship between VCTE and clinical outcomes. A total of 362 adult LT recipients with successful VCTE examination between 2015 and 2022 were included. Presence of advanced fibrosis was defined as liver stiffness
-
Development of Desmoid Tumors After Ileorectal Anastomosis Versus Ileal Pouch-Anal Anastomosis in Familial Adenomatous Polyposis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-04 Arthur S. Aelvoet, Maria Pellisé, Thymen N. Miedema, Maria Daca-Alvarez, Barbara A.J. Bastiaansen, Monique E. van Leerdam, Rodrigo Jover, Francesc Balaguer, Michal F. Kaminski, Francesco Buttitta, Luigi Ricciardiello, Niels Jespersen, John G. Karstensen, Patrick M.M. Bossuyt, Andrew Latchford, Roel Hompes, Evelien Dekker, European FAP Consortium
Desmoid tumors (DT) are an important cause of morbidity and mortality in patients with familial adenomatous polyposis (FAP). DT development might be related to the type and approach of colectomy. We aimed to compare DT development after colectomy with ileorectal anastomosis (IRA) and proctocolectomy with ileal pouch-anal anastomosis (IPAA). We performed an international historical cohort study in patients
-
Features of Gastrointestinal Strongyloidiasis Hyperinfection: Endoscopy and Histopathology Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-02 Udit Asija, Hanna Blaney, Sheila Kumar
-
First Report of Tirzepatide Hepatotoxicity with Jaundice Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-07-02 Robert J. Fontana, Eun-Young K. Choi, Josefa Kaganove, Alex Dodson
-
Reply Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-06-21 Olafur S. Palsson, B. Joseph Elmunzer